The Correlation of Anti-Acetylated Peptide Antibodies with Anti-Acetylated Lysine Peptide Antibodies and Anti-Acetylated Ornthinine Peptide Antibodies with Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease with a global prevalence of 0.24%–1%, requiring early diagnosis and aggressive treatment. It is associated with synovial and cartilage destruction. This study is designed to investigate the evaluation of anti-acetylated peptide antibodies (AAPA), acetylated lysine peptide antibodies (AcLys,), anti-acetylated ornthinine peptide antibodies (AcOrn), liver function test, and body mass index (BMI) in Rheumatoid arthritis patients. One hundred-ten RA patients (86.36% female, 13.63% male) in comparison with forty healthy controls. Anti-acetylated- peptide Antibodies (AAPA), Anti-acetylated Lysine peptide Antibodies (AcLys), Anti-acetylated-ornthinine peptide Antibody (AcOrn) were determined by Enzyme Linked Immunosorbent Assay (ELISA) and liver function levels were used to measure by spectrophotometer in the serum of RA patients and healthy controls. The mean∓SE of age in patients and healthy controls were 51 0.89 years and 49 1.48 years respectively. According to treatment, the patients of the study were divided into three subgroups [biology treatment (bDMARDs), conventional treatment (cDMARDs) subgroup and combined (DMARDs) subgroup]. The mean SE of AAPA in RA patients and healthy controls were 51.05 5.613 ng/mL and 19.98 3.29 ng/mL respectively. Results showed there was a significant increase between all subgroups of AAPAs (p < 0.001), AcOrns (p < 0.001) and AcyLs (p < 0.001) as compared to healthy control whereas there were no significant differences in AAPA between subgroups with each other’s. While AcOrns levels showed a significant increase in chemotherby as compared to biology subgroup (p < 0.0149), in addition levels of AcLys showed a significant increase in biology subgroup and biochemistry as compared to chemotherapy subgroups.